Table 5.
Fractures and arthralgia in adjuvant randomized trials comparing aromatase inhibitors to tamoxifen or placebo in breast cancer
| Study | ATAC Anastrozole vs tam (ATAC group 2005) | BIG 1–98 Letrozole vs tam (Coates 2007) | ABCSG8/ARNO95 Anastrozole vs tam (Jakecz 2005a) | IES Exemestane vs tam (Coombes 2007) | MA 17 Letrozole vs Placebo (Goss 2005) |
|---|---|---|---|---|---|
| Median follow-up | 68 months | 51 months | 55 months | 36 months | 28 months |
| Median exposure to AI | 5 years | 51 months | 3 years | 2–3 years | 2 years |
| Fractures | 11.0% vs 7.7%a | 8.6% vs 5.8%a | 2.0% vs 1.0%b | 4.3% vs 3.1%b | 5.3% vs 4.6%b |
| p < 0.0001 | p < 0.001 | p = 0.015 | p = 0.03 | p = 0.25 | |
| Arthalgia | 35.6% vs 29.4%a | 8.3% vs 3.8%b | N/A | 18.6% vs 11.8%b | 25.0% vs 21.0%b |
| p < 0.0001 | p < 0.0001 | p < 0 .0001 | p < 0.001 |
a
Prespecified.
b
Not prespecified.
Abbreviation: N/A, not available.